Loading
Funda Meric-Bernstam runs the world's largest phase 1 programme and led the tumour-agnostic HER2 ADC study.
Funda Meric-Bernstam is Chair of Investigational Cancer Therapeutics at MD Anderson Cancer Center, where she runs the world's largest phase 1 programme. A surgical oncologist turned early-drug-development leader, she directs MD Anderson's Institute for Personalized Cancer Therapy and chaired DESTINY-PanTumor02, the trial that led to the tumour-agnostic approval of trastuzumab deruxtecan for HER2 IHC 3+ solid tumours. Her papers report the primary results of the DESTINY-PanTumor02 phase II trial of trastuzumab deruxtecan in HER2-expressing solid tumours and the feasibility of large-scale genomic testing to enrol patients onto genomically matched trials. Her work spans precision oncology, comprehensive genomic profiling and companion diagnostics.
| Title | Journal | Year |
|---|---|---|
| Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial | Journal of Clinical Oncology | 2024 |
| Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials | Journal of Clinical Oncology | 2015 |
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan, HER2.
Shares Companion diagnostics, Comprehensive genomic profiling.
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan, HER2.
Shares Companion diagnostics, Comprehensive genomic profiling.
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan.
Shares Companion diagnostics, HER2.
Shares Companion diagnostics, Comprehensive genomic profiling.
Shares Trastuzumab deruxtecan, HER2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/